Active	Status	Sponsor type	Region	Phase	Filter
7 Active 3 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Evans, Stephanie
ADAPT, NCT05535920: A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia	Completed	4	88	US	LOKELMA 5 GM Powder for Oral Suspension	NephroNet, Inc., AstraZeneca	Hyperkalemia	04/24	04/24
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	380	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	09/23	12/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26
NCT03897777: Exercise, Hypertension, and Gut Dysbiosis in African Americans	Active, not recruiting	N/A	36	US	Exercise Training effect on Hypertension and Gut Dysbiosis	North Carolina Agriculture & Technical State University	Hypertension	06/26	06/26
Vo, Nam
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	380	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	09/23	12/26
NCT05514548: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Active, not recruiting	2	265	Europe, Canada, US, RoW	INV-202, None applicable, Placebo	Inversago Pharma Inc., Worldwide Clinical Trials	Diabetic Kidney Disease	07/24	09/24
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Chinook Therapeutics U.S., Inc.	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26